Ondrox Patent & News

“The present invention concerns a formulation of vitamins, minerals and other beneficial supplements which has been demonstrated to be cancer-protective. It is believed that the formulations of the present invention will also protect against cardiovascular disorders, extend longevity as well as to facilitate immunological integrity in humans.

More specifically, the invention is directed to a formulation and methods of manufacturing and administering a formulation containing vitamins and minerals in association with antioxidants, fish oils, enzymes, and amino acids. The formulations of the present invention provide synergistic relationships which have not previously been reported. As a preferred embodiment, the formulations of the present invention are manufactured as a sustained-release tableted dietary supplement and are intended as daily supplements.”

Source: U.S. Patent # 6,451,341
Additional: Ondrox™ formulation also has received a similar patent from the European Patent Office: # 0514451

In May of 1999, Ondrox™ received an endorsement from the National Foundation for Cancer Research (NFCR). NFCR has provided over $160 million to scientists around the world for basic research on cancer prevention and causation. One of the projects is led by Dr. Bruce Ames at the University of California at Berkeley, California, who received in April, 1999 the coveted National Medal for Science from President Clinton.

Dr. Ames conducted research on the impact of nutrition on health and found that certain key micronutrients play a very pivotal role in maintaining good health. A deficiency in some of these ingredients could cause damage to DNA similar to radiation. This in turn could lead to the promotion of cancer. Another conclusion from the research indicates most Americans do not consume the recommended five portions of fruits and vegetables every day. Therefore, taking daily supplements is an economic means to build up the body's own defenses against cancer and to prolong life expectancy.

The endorsement of Ondrox™ as a reliable and reputable source of nutrients by NFCR is its first and only act taken to help educate the public on the importance of nutrients in helping to prevent cancer. The endorsement is the outcome of a review of research data on the core formulation of Ondrox™ developed at M.D. Anderson Cancer Center in Texas, rated as the second best cancer treatment center in the U.S.

In recent months there has been extensive publicity about the discovery at M.D. Anderson Cancer Center of a specific chemical in cigarettes that is directly responsible for most lung cancers.

The research proves that the chemical causes damage to the p53 tumor suppressor gene that normally prevents the cancer cells from growing out of control. The finding was acclaimed by the scientific community as the most significant break through in establishing the direct link between cigarette and cancer.

At the same research park, animal tests originally performed to design an ideal antioxidant cocktail showed that the animals benefitted from the formulation by inhibiting the formation and progression of cancer, and indeed prolonging their life.

Recently, further progress in research has proven again in animal trials that even with the mutated oncogenes and absence of the tumor suppressor genes (p53 knock out gene), mice can live much longer if given certain anti-oxidants, and lower caloric intake. The mutated oncogenes cause cancer to grow, while the suppressor genes normally prevents cancer from developing or progressing. The latter are the same good genes that, if given certain antioxidants and a lower caloric intake, are capable of prolonging the animals' life even when their genes are adversely altered.